

# Comprehensive Molecular Profiling Final Report



## SAMPLE, Patient

Date of Birth: **01/11/1987** Gender: **Female**

Report Number: **S517**


Report Date: **13-Feb-2024**

Specimen Source/ID: **FFPE / 7323B14809**

Ordering Physician: **Prof. Dr. Sample Clinician**

Diagnosis: **CERVICAL CANCER**

### GENETIC RESULT: POSITIVE - CLINICALLY SIGNIFICANT MUTATIONS IDENTIFIED



## REPORT SUMMARY

The comprehensive genomic analysis of the sample tissue containing 10% tumor cells from the patient, **SAMPLE Patient**, revealed genomic markers: Low Tumor Mutation Burden (**TMB low, 3.9 muts/mb**), and Microsatellite Stability (**MS stable, unstable sites 0.9%**). In the same sample of tumor tissue, a comprehensive genomic analysis was performed for 523 genes and 55 transcripts, investigating point mutations, deletions, amplifications, and translocations. Pathogenic and potentially driving mutations were identified, including **PTEN (1 copy)** copy number loss, **EWSR1-FLI1 fusion**, **MED12 p.? C. 204+2T>G (VAF 48.4%)** mutation.

In addition to the above mutations, clinical significance unknown or not yet pathogenic (VUS) copy number changes were detected in the sample tissue, including **MDM4 (3 copies)** and **FGF8 (1 copy)**, as well as **NTRK1 p.E551K c.1651G>A variation (VAF 66%)**.

The detected EWSR1-FLI1 fusion in the patient supports the presence of a sarcomatoid component, suggesting the **possibility of genital system primary Ewing sarcoma**. Although rare, literature reports include 19 cases of cervical primary Ewing sarcoma, and there is also a case report of uterine primary Ewing sarcoma (PMID: 26549660, PMID: 33494989).

EWSR1-FLI1 fusion is an alteration that activates several oncogenic genes and accelerates the cell proliferation. According to the NCCN guidelines, these patients have been reported to benefit from alternating treatment with **vincristine, dactinomycin, cyclophosphamide, doxorubicin, ifosfamide, and etoposide**.

Loss of PTEN and copy number alterations were detected in our patient's tumor tissue, suggesting the potential activation of the RAS/PI3K/MEK-MAPK pathways. Therefore, it is considered that **trametinib or binimetinib treatment**, which inhibits these pathways, may be beneficial.

A MED12 p.? c.204+2T>G (VAF % 48.4) mutation has been identified in our patient. It has been reported that MED12 mutations are frequently encountered in uterine leiomyomas and leiomyosarcomas (PMID: 25108465). The neuroendocrine differentiation observed in our patient's pathology report may be consistent with histopathological findings of Ewing sarcoma.

If clinically deemed necessary, the use of the liquid biopsy tests can be considered for monitoring our patient.

## SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

### Clinically Relevant Results

#### Tier I - Strong Clinical Significance

#### CLINICAL IMPACT

##### PTEN Copy number loss (1 copy)

A

#### Interpretation

Copy number loss of the PTEN gene was identified (equivalent to 1 copy and a 0.56-fold change). PTEN deletions result in a loss-of-function and are known to be oncogenic (PMID: 28481359). PTEN encodes a tumor suppressor that is one of the most frequently mutated genes in human cancer (PMID: 9072974, 9090379, 22473468). PTEN has several physiological functions, most notably operating as a phosphatase that converts phosphatidylinositol (3,4,5)-triphosphate (PIP3) to phosphatidylinositol (4,5)-triphosphate (PIP2) at the cell membrane (PMID: 18767981, 28481359). PTEN deletions been reported in **prostate cancer**, 5.4% of large cell neuroendocrine cancers (PMID: 28481359). Loss of PTEN protein expression has been identified as a marker of poor prognosis in NSCLC (PMID: 21782507, 22982652). Loss of PTEN may also lead to greater genomic instability and provide a setting for the accumulation of other deleterious mutations (PMID: 28481359). Germline loss-of-function PTEN mutations occur in approximately 80% of patients with the cancer predisposition syndrome Cowden disease, which is associated with rare high-penetrance breast and thyroid cancer (PMID: 9467011, 24136893, 21430697, 28481359). This assay cannot distinguish between somatic (in tumor only) versus germline (inherited) changes. Clinical correlation is recommended.

#### Tier II - Potential Clinical Significance

#### CLINICAL IMPACT

##### EWSR1, FLI1 fusion transcript

C

Diagnostic of — Peripheral neuroectodermal tumor, Round cell sarcoma, Ewing's sarcoma of bone, or Ewing's sarcoma

#### Interpretation

A EWSR1-FLI1 fusion t(11;22)(q24.1-q24.3;q12.2)(chr22:g.29683123::chr11:g.128675261) has been identified in this tumour.

The genetics of EWS are characterized by a canonical fusion involving EWSR1 (Ewing's Sarcoma Region 1) gene and a member of the ETS family of transcription factors, such as FLI1 (Friend Leukaemia virus Integration 1) and ERG. If a gene fusion occurs in Ewing's sarcoma, most frequently it is the recurrent t(11;22)(q24;q12) translocation resulting in the fusion of EWSR1 and FLI1 genes, identified in 80-90% of cases (PMID: 3779625\_TurcCarel\_1986; PMID: 1522903\_Delattre\_1992; PMID: 8022439\_Delattre\_1994). The second most common molecular abnormality is the t(21;22)(q22;q12), which accounts for approximately 5-10% of the cases, resulting in an EWSR1-ERG fusion (PMID: 10561219\_Ginsberg\_1999; PMID: 26690869\_Chen\_2015).

Evidence suggests that fusion of EWS to different members of the ETS family of transcription factor genes may result in the expression of similar disease phenotypes (PMID: 8162068\_Sorenson\_1994). One study has shown that EWSR1-FLI1 and EWSR1-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma, with no significant differences observed between the two groups in age of diagnosis, sex, metastasis at diagnosis, primary site, event-free survival, or overall survival (PMID: 10561219\_Ginsberg\_1999). Recent reports from the EURO-EWING 99 study and the Children's Oncology Group study suggest that with currently available effective therapies, patients with Ewing sarcoma have similar outcomes, regardless of fusion subtype in contrast to some previous reports (see commentary by Barr & Meyer (PMID: 20308653\_2010). On the other hand, chromosomal translocation itself could be a treatment target of trabectedin, and the specific translocation of Ewing sarcoma could be the target of trabectedin. In a preclinical study, trabectedin inhibited NR0B1 expression by suppressing the activity of EWSR1-FLI1 and a partial response to recurrent/metastatic Ewing sarcoma was observed (PMID: 2469622\_Ueda\_2014).

## SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

### Tier II - Potential Clinical Significance

### CLINICAL IMPACT

#### MED12 p.? c.204+2T>G

NM\_005120.2

VAF % 48.4

DEPTH 403

D

#### Interpretation

MED12 encodes for a component of CDK8, which is involved in transcription initiation, and is involved in a variety of estrogen dependent tumors. The splice site variant identified is expected to result in protein truncation / inactivation and is likely oncogenic.

### POTENTIAL CLINICAL TRIALS

Clinical Trials associated with this patient's genomic profile and tumor type are displayed below.

TITLE	TRIAL IDENTIFIER	PHASE	VARIANT
Lurbinectedin in FET-Fused Tumors	NCT05918640 <a href="https://clinicaltrials.gov/show/NCT04848337">https://clinicaltrials.gov/show/NCT04848337</a>	I/II	EWSR1, FLI1 EWSR1-FLI1 fusion transcript

### TIER III - VARIANTS OF UNCERTAIN SIGNIFICANCE

<b>FGF8</b> Copy number loss in FGF8 (1 copy)	<b>MDM4</b> Copy number gain in MDM4 (3 copies)	<b>NTRK1</b> p.E551K NM_002529.3 c.1651G>A VAF 66% DEPTH 591
--	--	---

# SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

## CLASSIFICATION AND LEVELS OF EVIDENCE

The variant classification system used in this report is based on joint consensus recommendations of the Association for Molecular Pathology, American Society of Clinical Oncology, and the College of American Pathologists (J Mol Diagn 2017, 19:4-23). Tiers IA, IB, IIC, IID, III and IV describe variant categories of descending clinical significance in the patient. Variants in Tier IV are not reported in accordance with the consensus recommendations.

### IA

Variant of strong clinical significance, Level A evidence (FDA approved therapy or practice guideline in patient's tumor type)

### IB

Variant of strong clinical significance, Level B Evidence (consensus in the field based on well-powered studies in patient's tumor type)

### IIC

Variant of potential clinical significance, Level C evidence (FDA approved therapy or practice guideline in other tumor type(s), evidence from multiple small published studies, or based on availability of investigational therapies)

### IID

Variant of potential clinical significance, Level D evidence (case reports or preclinical studies)

### III

Variant of uncertain clinical significance

### III

Benign or likely benign variant

## REPORTED GENES

A total of 523 genes were subjected to targeted next generation sequencing analysis. Details available upon request.

## CGW VERSION

CGW\_v6.26

## DATABASE DETAILS

The versions, releases, builds, dates of the following databases were used to generate this report.

- Genomic Build: GRCh37.p13
- Genomic Annotation Sources: NCBI RefSeq v105
- gnomAD: r2.1
- dbNSFP: 3.5c
- COSMIC: v92
- NHLBI ESP: v.0.0.30
- ClinVar: 20210328
- dbSNP: 149
- ExAC: v1.0

# SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

## CODING EXON COVERAGE METRICS

Level 2: 100x coverage for > 50% of positions was not achieved for the targeted exon regions listed below:

Gene		
Transcript ID (Exon/Intron("))		
<b>FANCA</b>	<b>SDHA</b>	<b>FANCE</b>
NM_000135.2 (1)	NM_004168.2 (1)	NM_021922.2 (1)
<b>GPR124</b>	<b>INSR</b>	<b>TGFBR1</b>
NM_032777.9 (1)	NM_000208.2 (1)	NM_004612.2 (1)
<b>PTCH1</b>	<b>CCNE1</b>	<b>ARID1A</b>
NM_000264.3 (1)	NM_001238.2 (2)	NM_006015.4 (1)
<b>PTPRS</b>	<b>PTPRB</b>	<b>FGF3</b>
NM_002850.3 (15)	NM_007050.5 (1)	NM_005247.2 (1)
<b>RAB35</b>	<b>CDH1</b>	<b>FGF4</b>
NM_006861.6 (1)	NM_004360.3 (1)	NM_002007.2 (1)
<b>PDPK1</b>	<b>CEBPA</b>	<b>CENPA</b>
NM_002613.4 (2)	NM_004364.3 (1)	NM_001809.3 (1)
<b>KMT2B</b>	<b>BBC3</b>	<b>RB1</b>
NM_014727.1 (1)	NM_014417.4 (2)	NM_000321.2 (1)
<b>FLT3</b>	<b>FLT4</b>	<b>RECQL4</b>
NM_004119.2 (1)	NM_182925.4 (1)	NM_004260.3 (2)
<b>RET</b>	<b>PIK3R2</b>	<b>STAT5A</b>
NM_020975.4 (1)	NM_005027.3 (6)	NM_003152.3 (8)
<b>MAGI2</b>	<b>STAT5B</b>	<b>MALT1</b>
NM_012301.3 (22)	NM_012448.3 (7)	NM_006785.3 (1)
<b>IDH2</b>	<b>MAP2K4</b>	<b>GATA4</b>
NM_002168.2 (1)	NM_003010.3 (1)	NM_002052.3 (2)
<b>MAP3K1</b>	<b>NOTCH3</b>	<b>NOTCH3</b>
NM_005921.1 (1)	NM_000435.2 (24)	NM_000435.2 (1)

## PERTINENT NEGATIVES

Pertinent negatives were not reported for this case

# SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

## METHODOLOGY

**Pathology Assessment:** Pathologist reviews on H&E stained section of the tissue block or stained cytology slide were considered to assess adequacy and, as needed, guide enrichment of tumor for sequencing analysis. The in-house validation ensured that the samples passed all established laboratory QC metrics. This excludes exons, within the specified transcripts of the genes and listed in the Coding Exon Coverage Metrics section above, for which variants may not have been reliably detected.

**Assay Methods:** The test was performed using the Illumina TruSight™ Oncology 500 (TSO500) targeted hybrid-capture based next generation sequencing assay. It employs Unique molecular identifiers (UMI) to enable detection of variants, present in formalin-fixed paraffin-embedded (FFPE) tumor samples, at low VAFs with a high degree of sensitivity and specificity. TSO500 is designed to detect multiple classes of mutations including single-nucleotide variants (SNVs), multi-nucleotide variants (<3bp), small Insertions (1-18bp)/Deletions (1-27bp) and Copy Number Variants (CNVs). The assay also detects, quantitatively, microsatellite instability (MSI) and tumor mutational burden (TMB). Fusions and splice variants are detected in RNA. DNA and RNA are extracted from the same FFPE tissue using the Allprep DNA/RNA FFPE Kit (Qiagen, Inc.). RNA is then reverse transcribed to cDNA. The genomic DNA and cDNA are sheared to prepare sequencing libraries. The regions of interest are hybridized to biotinylated probes, magnetically pulled down with streptavidin-coated beads, and eluted to enrich the library pool. Finally, libraries are normalized using a simple beadbased protocol, then pooled and sequenced on an Illumina NovaSeq 6000 instrument.

**Secondary Analysis Methods:** The DNA and RNA data is analyzed using the Illumina Software TSO500 v2.2 Local App and a customized analysis pipeline within the Clinical Genomics Workspace software platform from PierianDx.

**Variant Calling:** Variants are reported according to HGVS nomenclature ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)) and classified as per the AMP classification system into tiers IA, IB, IIC, IID, III and IV. These tiers are stratified by clinical utility ('actionability' for clinical decision-making as to diagnosis, prognosis, treatment options, and carrier status) and previously reported data in the medical literature. Variations found in gnomAD (<https://gnomad.broadinstitute.org/>) that have  $\geq 1\%$  minor allele frequency (except those that are also in ClinVar denoted as clinically relevant, used in a clinical diagnostic assay, or reported as a mutation in a publication) are classified as known polymorphisms. Exons from some transcripts included in the RefSeq annotation release v105 found in genes reported in certain gene subsets of this test are not targeted by the assay. The untargeted exons are disclaimed and are identified as follows: HIST2H3A NM\_001005464.2 exon 1, HIST2H3C NM\_021059.2 exon 1, MYB NM\_001130173.1 exon 1, PAX8 NM\_003466.3 exon 8, PDPK1 NM\_002613.4 exon 3, PDPK1 NM\_002613.4 exon 8, PDPK1 NM\_002613.4 exon 1, PDPK1 NM\_002613.4 exon 6, PDPK1 NM\_002613.4 exon 4, PDPK1 NM\_002613.4 exon 5, PDPK1 NM\_002613.4 exon 9, PDPK1 NM\_002613.4 exon 10, RANBP2 NM\_006267.4 exon 13, RANBP2 NM\_006267.4 exon 8, REL NM\_002908.2 exon 9, SUZ12 NM\_015355.2 exon 3, FGF8 NM\_033164.3 exon 1, RECQL4 NM\_004260.3 exon 1, ICOSLG NM\_015259.4 exon 1, NOTCH1 NM\_017617.3 exon 1. Additionally, all small variant calls in the HLA-A, KMT2B, KMT2C, and KMT2D genes are filtered out due to potential mis-mapping as a result of sequence homology with other genomic regions.

### Notes:

- This assay does not detect complex structural alterations or indels, with the exception of a subset of clinically relevant complex EGFR exon 19 indels that are specifically targeted. Variants located outside of targeted regions too will not be detected.
- It is possible that pathogenic variants may not be reported by one or more of the tools because of the parameters used. However, tool parameters were optimized to maximize specificity and sensitivity.

## DISCLAIMER

This Report was generated using the materials and methods described above, which required the use of various reagents, protocols, instruments, software, databases, and other items, some of which were provided or made accessible by third parties. A defect or malfunction in any such reagents, protocols, instruments, software, databases, and/or other items may compromise the quality or accuracy of the Report. The Report has been created based on, or incorporates references to, various scientific manuscripts, references, and other sources of information, including without limitation manuscripts, references, and other sources of information that were prepared by third parties that describe correlations between certain genetic mutations and particular diseases (and/or certain therapeutics that may be useful in ameliorating the effects of such diseases). Such information and correlations are subject to change over time in response to future scientific and medical findings. PierianDx makes no representation or warranty of any kind, expressed or implied, regarding the accuracy of the information provided by or contained in such manuscripts, references, and other sources of information. If any of the information provided by or contained in such manuscripts, references, and other sources is later determined to be inaccurate, the accuracy and quality of the Report may be adversely impacted. PierianDx is not obligated to notify you of any impact that future scientific or medical research findings may have on the Report.

---

**SAMPLE, Patient**Date of Birth: **01/11/1987**Gender: **Female**Report Number: **S517**Report Date: **13-Feb-2024**

---

The Report must always be interpreted and considered within the clinical context, and a physician should always consider the Report along with all other pertinent information and data that a physician would prudently consider prior to providing a diagnosis to a patient or developing and implementing a plan of care for a patient. The Report should never be considered or relied upon alone in making any diagnosis or prognosis. The manifestation of many diseases are caused by more than one gene variant, a single gene variant may be relevant to more than one disease, and certain relevant gene variants may not have been considered in the Report. In addition, many diseases are caused or influenced by modifier genes, epigenetic factors, environmental factors, and other variables that are not addressed by the Report (or that are otherwise unknown). This Report is based on a next generation sequencing assay which does not distinguish between somatic and germline variants. If a germline variant is in question, further testing may be recommended. As such, the relevance of the Report should be interpreted in the context of a patient's clinical manifestations. The Report provided by PierianDx is provided on an "AS IS" basis. PierianDx makes no representation or warranty of any kind, expressed or implied, regarding the Report. In no event shall PierianDx be liable for any actual damages, indirect damages, and/or special or consequential damages arising out of or in any way connected with the Report, your use of the Report, your reliance on the Report, or any defect or inaccurate information included within the Report.

Medical knowledge annotation is constantly updated and reflects the current knowledge at the time.

The test performance characteristics were determined by the PierianDx Molecular Laboratory. The Report was generated by the PierianDx Molecular Laboratory as required by the CLIA 1988 regulations. The Report, and the tests used to generate the Report, have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The test results have been shown to be clinically useful. This laboratory is CLIA certified to perform high complexity testing.

This **Authorized Signature**  
pertains to this laboratory report:

**Prof.Dr. M.Cengiz Yakicier**  
NPG Genetic Diseases  
Evaluation Center  
Responsible Medical Dr.  
Center Manager

## SAMPLE, Patient

Date of Birth: 01/11/1987

Gender: Female

Report Number: S517

Report Date: 13-Feb-2024

### REFERENCES

- PMID 1522903:** (Delattre O, et al.; Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.; *Nature*; 1992 Sep 10;359(6391):162-5)
- PMID 2469622:** (Hallam SE, Malpartida F, Hopwood DA; Nucleotide sequence, transcription and deduced function of a gene involved in polyketide antibiotic synthesis in *Streptomyces coelicolor*.; *Gene*; 1988 Dec 30;74(2):305-20)
- PMID 3779625:** (Turc-Carel C, et al.; Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas.; *Cancer Genet Cytogenet*; 1986 Dec;23(4):291-9)
- PMID 8022439:** (Delattre O, et al.; The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts.; *N Engl J Med*; 1994 Aug 4;331(5):294-9)
- PMID 8162068:** (Sorensen PH, et al.; A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.; *Nat Genet*; 1994 Feb;6(2):146-51)
- PMID 9072974:** (Li J, et al.; PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.; *Science*; 1997 Mar 28;275(5308):1943-7)
- PMID 9467011:** (Marsh DJ, et al.; Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.; *Hum Mol Genet*; 1998 Mar;7(3):507-15)
- PMID 10561219:** (Ginsberg JP, et al.; EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma.; *J Clin Oncol*; 1999 Jun;17(6):1809-14)
- PMID 18767981:** (Chalhoub N, Baker SJ; PTEN and the PI3-kinase pathway in cancer.; *Annu Rev Pathol*; 2009;4:127-50)
- PMID 20308653:** (Barr FG, Meyer WH; Role of fusion subtype in Ewing sarcoma.; *J Clin Oncol*; 2010 Apr 20;28(12):1973-4)
- PMID 21782507:** (O'Byrne KJ, et al.; Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.; *Lancet Oncol*; 2011 Aug;12(8):795-805)
- PMID 25108465:** (Heinonen HR, et al.; MED12 mutation frequency in unselected sporadic uterine leiomyomas.; *Fertil Steril*; 2014 Oct;102(4):1137-42)
- PMID 26549660:** (Mashriqi N, et al.; Ewing's sarcoma of the cervix, a diagnostic dilemma: a case report and review of the literature.; *J Med Case Rep*; 2015 Nov 9;9:255)
- PMID 26690869:** (Chen S, et al.; Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH.; *Genes Chromosomes Cancer*; 2016 Apr;55(4):340-9)
- PMID 28481359:** (Zehir A, et al.; Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.; *Nat Med*; 2017 Jun;23(6):703-713)
- PMID 33494989:** (Wu YC, Kao YC, Chang CW; Primary uterine Ewing sarcoma - A case report.; *Taiwan J Obstet Gynecol*; 2021 Jan;60(1):142-144)